Gastric cancer and adenocarcinoma of the esophagogastric junction: Principles of neoadjuvant therapy;Magen- und adenokarzinome des ösophagogastralen übergangs: Prinzipien der neoadjuvanten therapie

Chirurg

Volumn 82, Issue 11, 2011, Pages 968-973

  Lordick, F ^a   Ott, K ^b   Sendler, A ^c  

^a KLINIKUM BRAUNSCHWEIG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Chirurgische Klinik   (Germany)

Author keywords

Chemotherapy; Esophageal cancer; Gastric cancer; Neoadjuvant; Radiation

Indexed keywords

ADENOCARCINOMA; ADJUVANT THERAPY; ARTICLE; CANCER STAGING; ESOPHAGUS TUMOR; HUMAN; LOWER ESOPHAGUS SPHINCTER; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS; STOMACH TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; GUIDELINE ADHERENCE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 80855156724     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-011-2127-3     Document Type: Article

References (45)

1. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376(9742):687-697
2. Becker K, Langer R, Reim D et al (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253(5):934-939
3. Cho JY, Lim JY, Cheong JH et al (2011) Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 17(7):1850-1857
4. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11-20
5. Feussner H, Härtl F (2006) Staging laparoscopy in oncology. Chirurg 77(11):971-980
6. Fiorica F, Di Bona D, Schepis F et al (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53(7):925-930
7. Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127(9):2209-2221
8. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137-2150
9. Langer R, Ott K, Feith M et al (2009) Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 22(12):1555-1563
10. Lordick F (2011) Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 7(2):187-199
11. Lordick F, Grenacher L, Röcken C et al (2010) Diagnosis and treatment of gastric cancer. Dtsch Med Wochenschr 135(34-35):1671-1682
12. Lordick F, Jäger D (2008) Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. Gastrointest Cancer Res 2(4):187-197
13. Lordick F, Luber B, Lorenzen S et al (2010) Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102(3):500-505
14. Lordick F, Ott K, Krause BJ (2011) Positron emission tomography - current role in the diagnosis and treatment of upper gastrointestinal carcinomas. Dtsch Med Wochenschr 136(20):1061-1066
15. Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8(9):797-805
16. Lordick F, Ott K, Novotny A et al (2007) R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences. Chirurg 78(9):792-801
17. Lordick F, Ott K, Weitz J, Jäger D (2008) The evolving role of catumaxomab in gastric cancer. Expert Opin Biol Ther 8(9):1407-1415
18. Lordick F, Ruers T, Aust DE et al (2008) European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 44(13):1807-1819
19. Lordick F, Stein HJ, Peschel C, Siewert JR (2004) Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91(5):540-551
20. Meining A, Dittler HJ, Wolf A et al (2002) You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut 50(5):599-603
21. Meyer zum Büschenfelde C, Herrmann K, Schuster T et al (2011) 18F-FDG PET-Guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II Trial. J Nucl Med [Epub ahead of print]
22. Moehler M, Al-Batran SE, Andus T et al (2011) German S3-guideline "Diagnosis and treatment of esophagogastric cancer". Z Gastroenterol 49(4):461-531
23. Ott K, Bader FG, Lordick F et al (2009) Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol 16(4):1017-1025
24. Ott K, Herrmann K, Schuster T et al (2011) Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol [Epub ahead of print]
25. Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21(24):4604-4610
26. Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24(29):4692-4698
27. Ribi K, Koeberle D, Schuller JC et al (2009) Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer [Epub ahead of print]
28. Schuhmacher CP, Fink U, Becker K et al (2001) Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91(5):918-927
29. Schuhmacher C, Gretschel S, Lordick F et al (2010) Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28(35):5210-5218
30. Sendler A, Etter M, Böttcher K, Siewert JR (2002) Extent of resection in surgery of stomach carcinoma. Chirurg 73(4):316-324
31. Sendler A, Gilbertz KP, Becker I et al (2001) Proliferation kinetics and prognosis in gastric cancer after resection. Eur J Cancer 37(13):1635-1641
32. Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12(7):681-692
33. Siewert JR, Lordick F (2006) Response prediction - early response evaluation. Consequences for surgical oncology. Chirurg 77(12):1095-1103
34. Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85(11):1457-1459
35. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM Classification of malignant tumours. 7. Aufl. John Wiley & Sons, New York
36. Stahl A, Ott K, Weber WA et al (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30(2):288-295
37. Stahl M, Wilke H, Stuschke M et al (2005) Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 131(1):67-72
38. Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27(6):851-856
39. Ströhlein MA, Lordick F, Rüttinger D et al (2011) Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie 34(3):101-108
40. Vallböhmer D, Hölscher AH, Dietlein M et al (2009) [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 250(6):888-894
41. Van Cutsem E, Dicato M, Geva R et al (2011) The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 22(Suppl 5):1-9
42. Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19(12):3058-3065
43. Wieder HA, Beer AJ, Lordick F et al (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46:2029-2034
44. Wilke H, Preusser P, Fink U et al (1991) New developments in the treatment of gastric carcinoma. Cancer Treat Res 55:363-373
45. Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(13):1715-1721